Valuation: Larimar Therapeutics, Inc.

Market Cap 398M 348M 321M 295M 559M 38.27B 568M 3.83B 1.5B 18.7B 1.49B 1.46B 64.47B P/E 2026 *
-2.36x
P/E 2027 * -3.06x
Enterprise Value 221M 193M 178M 164M 311M 21.29B 316M 2.13B 836M 10.41B 831M 813M 35.87B EV / Sales 2026 *
-
EV / Sales 2027 * 3.33x
Free-Float
96.75%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Larimar Therapeutics, Inc.

1 day+2.42%
1 week+5.54%
Current month+24.92%
1 month+6.13%
3 months-21.12%
6 months+16.87%
1 week 3.56
Extreme 3.5603
4.32
1 month 2.92
Extreme 2.92
4.32
Current year 2.72
Extreme 2.715
6.42
1 year 2.72
Extreme 2.715
6.42
3 years 1.61
Extreme 1.61
13.68
5 years 1.53
Extreme 1.53
15.26
10 years 1.53
Extreme 1.53
25.87
Manager TitleAgeSince
Chief Executive Officer 67 2020-04-30
Director of Finance/CFO 67 2020-05-27
Chief Tech/Sci/R&D Officer 65 2023-07-16
Director TitleAgeSince
Director/Board Member 67 2019-12-31
Chairman 61 2020-05-27
Director/Board Member 58 2020-05-27
Date Insider Type Main position Quantity % Market Cap.
07-05Buy

Director

50,000 0.0584%
05-18Free

Director

55,150 0.0644%
05-18Free

Director

55,150 0.0644%
Change 5-day change 1-year change 3-year change Capi.($)
+2.42%+5.54%+20.57%+18.69% 388M
+3.13%+13.95%+64.21%+94.35% 55.93B
-1.39%-6.15%+56.05%+124.73% 54.49B
-0.27%-5.77%+6.75%+433.06% 23.87B
+1.76%-1.65%-16.86%-15.01% 22.86B
+1.62%+8.47%+47.79%-1.59% 20B
+1.94%+0.21%+39.31%-27.77% 17.48B
+10.00%-4.30%+208.33%+370.99% 15.39B
-2.70%+10.11%+47.16%+700.31% 15.19B
-0.39%-1.00%+26.08%+186.49% 14.02B
Average +1.63%+1.27%+49.94%+188.42% 23.96B
Weighted average by Cap. +1.30%+0.50%+51.58%+169.10%

Financials

2026 *2027 *
Net sales - 57.06M 49.89M 46.02M 42.31M 80.16M 5.49B 81.53M 549M 216M 2.68B 214M 210M 9.25B
Net income -157M -138M -127M -117M -221M -15.15B -225M -1.52B -595M -7.4B -591M -578M -25.52B -157M -137M -126M -116M -220M -15.07B -224M -1.51B -592M -7.37B -588M -575M -25.39B
Net Debt -176M -154M -142M -131M -248M -16.97B -252M -1.7B -666M -8.3B -662M -648M -28.59B -208M -182M -168M -154M -292M -20B -297M -2B -785M -9.78B -781M -764M -33.7B
Logo Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Employees
71
Date Price Change Volume
26-07-15 US$3.810 +2.42% 1,268,162
26-07-14 US$3.720 -0.13% 1,842,147
26-07-13 US$3.725 -12.97% 2,297,804
26-07-10 US$4.280 +3.63% 3,445,587
26-07-09 US$4.130 +14.40% 3,823,933
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
3.810USD
Average target price
14.40USD
Spread / Average Target
+277.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LRMR Stock